Back

The impact of the catheter ablation on long-term prognosis in patients with hypertrophic cardiomyopathy and atrial fibrillation

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Arrhythmias and cardiomyopathy Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Lei Ding

Fuwai Hospital, CAMS and PUMC, Beijing (China)

6 More presentations in this session

Presentation thumbnail
Right atrial remodeling after pulmonary vein isolation: analyzing changes in volume and function using cardiac MRI
Ms N. Van Pouderoijen (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Heart failure and stroke risk in atrial fibrillation: temporal trends from a nationwide cohort study
Doctor E. Jalli (Pori, FI)
Abstract Slides Video
Presentation thumbnail
P-wave morphology based diagnosis of atrial cardiomyopathy in heart failure with preserved ejection fraction (HFpEF) patients with and without known atrial fibrillation (AF)
Miss S. Haack (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Atrial cardiomyopathy is caused by folate-resistence via endothelial and endothelial progenitor cell dysfunction
Doctor L. Sgarra (Acquaviva Delle Fonti, IT)
Abstract Slides Video
Presentation thumbnail
Bundle branch block (BBB) adversely impacts heart failure outcomes in heart failure (HF) with preserved ejection fraction (pEF): A TOPCAT substudy
Doctor S. Saksena (Warren, US)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmias and cardiomyopathy

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Effect of catheter ablation vs medical therapy on cardiovascular outcomes in hypertrophic cardiomyopathy with atrial fibrillation
thumbnail
Congress Presentation
Long-term efficacy and safety of ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Pulsed-field vs thermal catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources